PB-950 | 648896-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: PB-950
• 英文别名: 8-Hydroxy-N-[2-(pyridin-2-yl)ethyl]quinoline-2-carboxamide；8-hydroxy-N-(2-pyridin-2-ylethyl)quinoline-2-carboxamide
• CAS: 648896-07-5
• 化学式: C₁₇H₁₅N₃O₂
• 分子量: 293.325
• InChiKey: YPAARDHXSLQZTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] 8-HYDROXY QUINOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINOLINE 8-HYDROXY
  申请人：PRANA BIOTECHNOLOGY LTD

  公开号：WO2004007461A1

  公开（公告）日：2004-01-22

  The present invention relates to a method for the treatment, amelioration and/or prophylaxis of a neurological condition, in particular neurodegenerative disorders which comprises the administration of an effective amount of a compound of formula (I): to a subject in need thereof. The present invention also relates to a compound of formula (II) and processes for its preparation.

  本发明涉及一种用于治疗、改善和/或预防神经系统疾病，特别是神经退行性疾病的方法，包括向需要的受试者施用化合物(I)的有效量。本发明还涉及一种化合物(II)及其制备方法。
• 8-HYDROXY QUINOLINE DERIVATIVES
  申请人：PRANA BIOTECHNOLOGY LIMITED

  公开号：US20150094334A1

  公开（公告）日：2015-04-02

  The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明描述了一种治疗受试者神经疾病的方法，包括向需要治疗的受试者施用公式中的化合物或其药学上可接受的盐、水合物或溶剂化物的治疗有效量。
• 8-Hydroxy quinoline derivatives
  申请人：Barnham Kevin Jeffrey

  公开号：US20080161353A1

  公开（公告）日：2008-07-03

  The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明描述了一种治疗主体神经系统疾病的方法，该方法包括向需要治疗的主体中给予一定治疗效果的化合物，该化合物的化学式如下，或其药学上可接受的盐、水合物或溶剂化物。
• Method of treatment of age-related macular degeneration (AMD)
  申请人：Prana Biotechnology Ltd

  公开号：EP2514423A2

  公开（公告）日：2012-10-24

  The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.

  本发明一般涉及视网膜变性疾病的治疗和预防领域。更具体地说，本发明考虑了一种方法，用于预防、降低哺乳动物，尤其是人类的老年性黄斑变性（AMD）或相关视网膜疾病的发病风险，或以其他方式治疗或改善其症状。本发明进一步提供了治疗组合物，可根据剂量或剂量特异性给药，用于治疗和预防老年性黄斑变性或相关视网膜退行性病变。
• Treatment of neurological conditions
  申请人：Masters Louis Colin

  公开号：US20070037848A1

  公开（公告）日：2007-02-15

  The present invention relates generally to the treatment of conditions and/or disorders associated with or exacerbated by oxidative stress and which have symptoms including cognitive impairment such as pre- or mild cognitive impairment or memory loss. The agents and methods useful for the practice of the present invention are proposed to modulate and in particular reduce levels of reactive oxygen species thereby minimizing oxidative stress. The present invention further provides methods and agents for the treatment of and/or prophylaxis of neurological diseases and in particular those associated with or facilitated by oxidative stress. Neurological disorders contemplated herein include any condition leading to cognitive impairment such as pre- or mild cognitive impairment or memory loss. The present invention provides therefore methods and agents for treating, ameliorating the symptoms of and/or otherwise arresting cognitive impairment such as pre- or mild cognitive impairment or memory loss.